Skip to content

FDA Approves Breast Cancer Treatment That Health Care Professionals Can Give at Home

The World’s Best Cities for Foodies

It’s one of life’s greatest joys, and perhaps the one we’ve missed the most, over these past few months—eating good food, especially around a table packed with friends. Whether a 10-course tasting menu at a Michelin-starred restaurant or a simple street-food meal, culinary pleasures are some of the very best parts of travel. And if you’re going for gastronomic gold, some places provide more treasures than most. Here’s our list of the world’s finest culinary cities—places worth the visit, simply for the food they put on your plate. Palacio de Bellas Artes, Mexico City. (David Carballar/Unsplash)Mexico City Drawing on Aztec and Mayan culinary traditions dating back more than 10,000 years, Mexican cuisine was bestowed a rare honor by UNESCO, which recognized it as an “intangible cultural heritage.” Corn, chilies, even…

FDA Approves Breast Cancer Treatment That Health Care Professionals Can Give at Home

The Food and Drug Administration (FDA) on June 29 approved Phesgo, a breast cancer treatment that can be administered at home by health care professionals.

Phesgo is a fixed-dose combination of two monoclonal antibodies and it allows treatment for both early and metastatic HER2-positive breast cancer for outpatients. The two monoclonal antibodies are pertuzumab, trastuzumab, and the combination also includes hyaluronidase, a substance that is injected into the patient to increase absorption of the medication. The treatment’s approval was granted to Genentech Inc.

The FDA said the HER2-positive breast cancer makes up about one-fifth of breast cancer cases and occurs due to an excess of a protein called epidermal growth factor receptor 2 (HER2) which promotes the growth of cancer cells.

“Pertuzumab and trastuzumab bind to sites on HER2 and disrupt signaling to stop cancer cell growth,” noted the FDA in a statement. “Phesgo is initially used in combination with chemotherapy and could continue to be administered at home by a qualified health care professional once the chemotherapy regimen is finished.”

Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases at the FDA’s Center for Drug Evaluation and Research, said currently most of the patients right now receive pertuzumab and trastuzumab at infusion centers.

“With a new administration route, Phesgo offers an out-patient option for patients to receive trastuzumab and pertuzumab,” said Pazdur in a statement adding that the health authorities keep a strong focus on patients with cancer as they are also vulnerable to the CCP virus, also called the novel coronavirus.

FDA Approves Breast Cancer Treatment That Health Care Professionals Can Give at Home (Illustration – Shutterstock)

“At this critical time, we continue to expedite oncology product development. This application was approved about four months ahead of the FDA goal date,” he said.

The FDA officials said the administration’s approval for Phesgo came after a noninferiority study in patients with HER2-positive early breast cancer. Noninferiority trials test to see if a new experimental treatment is less effective than an existing one.

The treatment does have some side effects—hair loss, nausea, diarrhea, anemia, and lack of energy. “Phesgo can cause worsening of chemotherapy-induced neutropenia (low level of white blood cells),” said the FDA.

The officials warned pregnant women that Phesgo can cause harm to a developing fetus or a newborn baby. “The FDA advises health care professionals to inform females of reproductive age that exposure to Phesgo during pregnancy or within 7 months prior to conception can result in fetal harm,” the FDA said.

The officials also advised that patients with anaphylaxis or severe allergic reaction or severe hypersensitivity should discontinue Phesgo.

Follow Venus on Twitter: @venusupadhayaya

Focus News: FDA Approves Breast Cancer Treatment That Health Care Professionals Can Give at Home

China’s Factory Activity Likely Slowed in June on Subdued Global Demand

BEIJING—China’s factory activity likely grew for the fourth month in June but the pace may be waning, as global demand stayed subdued while a fresh CCP (Chinese Communist Party) virus outbreak in the Chinese capital and rising worldwide cases threaten to undermine a gradual domestic recovery. The official manufacturing Purchasing Manager’s Index (PMI), due for release on June 30, is expected to ease to 50.4 in June, from 50.6 in May, according to the median forecast of 29 economists polled by Reuters. A reading above 50 indicates an expansion in activity. With travel bans finally lifted in April in Wuhan, the epicenter of the country’s CCP virus crisis, China has largely managed to recover from strict lockdowns that had led to weeks of economic paralysis. Yet export demand has remained…